Christopher Rovaldi

Insider Reports History

Location
Cambridge, MA
Signature
/s/ Keith Regnante, Attorney-in-Fact
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Christopher Rovaldi:

Company Role Class Num Shares Value Price $ Report Date Ownership
Keros Therapeutics, Inc. Chief Operating Officer Common Stock 60,000 $2,640,600 $44.01 18 Feb 2025 Direct

Insider Reports Filed by Christopher Rovaldi

Symbol Company Period Transactions Value $ Form Type Role Filing Time
KROS Keros Therapeutics, Inc. 18 Feb 2025 1 $0 4 Chief Operating Officer 19 Feb 2025, 16:15
KROS Keros Therapeutics, Inc. 13 Feb 2024 1 $0 4 CHIEF OPERATING OFFICER 15 Feb 2024, 20:38
KROS Keros Therapeutics, Inc. 16 Feb 2023 1 $0 4 Chief Operating Officer 17 Feb 2023, 15:19
KROS Keros Therapeutics, Inc. 06 Apr 2022 3 -$84,672 4 Chief Operating Officer 08 Apr 2022, 16:21
KROS Keros Therapeutics, Inc. 01 Apr 2022 7 -$35,851 4 Chief Operating Officer 05 Apr 2022, 16:31
KROS Keros Therapeutics, Inc. 01 Feb 2022 1 $0 4 Chief Operating Officer 03 Feb 2022, 15:45
KROS Keros Therapeutics, Inc. 01 Feb 2022 0 $0 3 Chief Operating Officer 03 Feb 2022, 15:37